Probiotics showed no clear difference in maintenance of clinical remission (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
It is very uncertain whether probiotics changes serious adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
It is very uncertain whether 6‐Mercaptopurine changes failure to maintain remission compared with 5‐ASA (very low certainty).
It is very uncertain whether azathioprine or 6‐mercaptopurine changes clinical remission compared with 5‐ASA or Sulfasalzine (very low certainty).
Azathioprine or 6‐mercaptopurine showed no clear difference in withdrawals due to adverse events compared with 5‐ASA or Sulfasalzine (low certainty).
It is very uncertain whether methotrexate changes maintenance of remission compared with 5‐ASA (very low certainty).
It is very uncertain whether methotrexate changes failure to enter remission or possible remission at 30 weeks… compared with 5‐ASA (very low certainty).
It is very uncertain whether methotrexate changes withdrawal due to adverse event (Maté‐Jiménez 2000) compared with 5‐ASA (very low certainty).
It is very uncertain whether methotrexate changes proportion of patients achieved clinical remission compared with 5‐aminosalicylic acid (5‐ASA) (very low certainty).